| Literature DB >> 33283770 |
Shrilaxmi Bagali1, Savitri M Nerune2, R Chandramouli Reddy3, Saeed M Yendigeri4, Bheemshetty S Patil5, Akram A Naikwadi6, Raghavendra V Kulkarni7, Kusal K Das1.
Abstract
OBJECTIVE: Patients exposed to chronic sustained hypoxia frequently develop cardiovascular disease risk factors to ultimately succumb to adverse cardiovascular events. In this context, the present study intends to assess the role of cilnidipine (Cil), a unique calcium channel blocker that blocks both L-type and N-type calcium channels, on cardiovascular pathophysiology in face of chronic sustained hypoxia exposure.Entities:
Keywords: Cardiovascular histopathology; cardiovascular remodeling; chronic hypoxia; cilnidipine; heart rate variability; normalized wall index
Year: 2020 PMID: 33283770 PMCID: PMC8025765 DOI: 10.4103/ijp.IJP_136_20
Source DB: PubMed Journal: Indian J Pharmacol ISSN: 0253-7613 Impact factor: 1.200
Study groups
| Serial number | Groups | Intervention |
|---|---|---|
| 1 | Group 1 (control) | Na CMC (0.5%) by oral gavage for 21 days |
| 2 | Group 2 (CH) | CH + Na CMC (0.5%) by oral gavage for 21 days |
| 3 | Group 3 (Cil) | Cil (2.0 mg/kg/day) in Na CMC (0.5%) by oral gavage for 21 days |
| 4 | Group 4 | CH + Cil (2.0 mg/kg/day) in Na CMC (0.5%) by oral gavage for 21 days |
n=6 in each group. Cil=Cilnidipine, Na CMC=Sodium carboxymethylcellulose, wt=Weight, CH: Chronic hypoxia
Comparison of heart rate variability and cardiovascular hemodynamics among groups of experimental animals (n=6 in each group)
| Parameter | Group 1 (control) | Group 2 (CH) | Group 3 (cil) | Group 4 (CH+cil) | ANOVA | |
|---|---|---|---|---|---|---|
| LF (nu) | ||||||
| Pre | 47.26±1.73a | 49.14±2.16a | 47.12±2.08a | 48.26±2.08a | 0.87 | 0.483 |
| Post | 45.59±1.87a | 61.39±2.52b | 33.17±2.09c | 53.24±2.99d | 99.02 | 0.000* |
| Paired | 0.088 | 0.0008* | 0.0002* | 0.0055* | ||
| Percentage change | 3.7±2.46a | 24.98±4.01b | 29.61±2.62b | 10.28±2.73c | 65.31 | 0.000* |
| HF (nu) | ||||||
| Pre | 53.53±2.63a | 51.15±2.70a | 52.69±2.89a | 51.72±3.35 a | 0.522 | 0.675 |
| Post | 55.18±2.41a | 37.79±2.04b | 58.03±3.58a | 49.85±2.53a | 43.73 | 0.000* |
| Paired | 0.08 | 0.004* | 0.001* | 0.38 | ||
| Percentage change | 3.10±2.34a | 25.95±5.78b | 10.11±1.71a | 6.70±2.64a | 33.16 | 0.000* |
| LF/HF | ||||||
| Pre | 0.88±0.05a | 0.95±0.05a | 0.88±0.042a | 0.93±0.07a | 1.65 | 0.228 |
| Post | 0.84±0.02a | 1.62±0.13b | 0.55±0.05c | 0.96±0.15a | 73.89 | 0.000* |
| Paired | 0.06 | 0.002* | 0.000* | 0.59 | ||
| Percentage change | 5.19±3.46a | 70.33±16.88b | 40.70±8.15c | 10.91±6.74a | 35.31 | 0.000* |
| Heart rate (beats/min) | ||||||
| Pre | 321.61±42.80a | 290.00±22.44a | 314.75±28.36a | 323.66±15.82a | 1.331 | 0.314 |
| Post | 294.29±49.49a | 284.52±20.33a | 262.95±8.37a | 306.00±14.00a | 1.489 | 0.271 |
| Paired | 0.004* | 0.04* | 0.000* | 0.01* | ||
| Percentage decrease in heart rate | 8.65±3.22a | 2.74±1.51b | 16.38±1.07c | 5.44±1.87a | 27.62 | 0.000* |
| MAP (mmHg) | ||||||
| Pre | 91.25±2.69a | 92.37±4.78a | 93.00±3.16a | 91.00±2.58a | 0.306 | 0.821 |
| Post | 96.75±1.70a | 108.50±6.60b | 99.75±2.87a | 84.00±4.32c | 23.39 | 0.000* |
| Paired | 0.001* | 0.01* | 0.002* | 0.02* | ||
| Percentage change in MAP | 6.05±1.22a | 17.54±6.63b | 7.26±1.76a | −6.61±1.70a | 9.309 | 0.002* |
Values are presented as Mean±SD. Intergroup comparison of each parameter is presented horizontally. Horizontally the superscripts a, b, c, d are indicative of values that differ significantly from one another (P<0.05). Intragroup comparison (pre vs. post) of each parameter by paired t-test is presented vertically, *P<0.05. LF=Low frequency, HF=High frequency; nu=Normalized units, MAP=Mean arterial pressure, SD=Standard deviation
Comparison of biomarkers of endothelial function (n=6 in each group)
| Parameter | Group 1 (control) | Group 2 (CH) | Group 3 (cil) | Group 4 (CH+cil) | ANOVA | |
|---|---|---|---|---|---|---|
| Serum VEGF (pg/ml) | 60.00±9.93a | 110.82±7.61b | 60.50±11.47a | 89.33±7.02c | 27.32 | 0.000* |
| Serum NOS3 (pg/ml) | 16.59±2.86a | 35.04±6.62b | 12.67±2.36a | 31.54±2.993b | 26.69 | 0.000* |
| Serum NO (µmol/L) | 11.21±2.63a | 6.95±1.76b | 10.04±1.25a | 9.38±1.81a | 3.24 | 0.056 |
Values are presented as mean±SD. Intergroup comparison of each parameter is presented horizontally. Horizontally the superscripts a, b, c are indicative of values that different significantly from one another (P<0.05). *P<0.05. NOS3=Endothelial nitric oxide synthase, NO=Nitric oxide; VEGF=Vascular endothelial growth factor, SD=Standard deviation
Figure 1Comparison of cardiosomatic index among groups (n = 6 in each group). Superscripts a, b, c represent a significant difference between groups. “a” depicts comparison with Group 1, “b” depicts comparison with Group 2. *P < 0.05
Figure 2Photomicrograph of the ventricular tissue with coronary artery stained with hematoxylin and eosin stain from (a) Group 1 (control) (×10), (b) Group 1 (control) (×40); (c) group 2 (CH) (×10), (d) Group 2 (CH) (×40); (e) Group 3 (Cil) (×10), (f) Group 3 (Cil) (×40); (g) Group 4 (CH + Cil) (×10), (h) Group 4 (CH + Cil) (×40). A: Nuclear enlargement, B: Myocardial hypertrophy, C: dilatation of coronary artery. CH: Chronic hypoxia, Cil: Cilnidipine
Figure 3Photomicrograph of elastic artery stained with hematoxylin and eosin stain from (a) Group 1 (control) (×10), (b) Group 1 (control) (×40); (c) Group 2 (CH) (×10); (d) Group 2 (CH) (×40); (e) Group 3 (Cil) (×10); (f) Group 3 (Cil) (×40); (g) Group 4 (CH + Cil) (×10); (h) Group 4 (CH + Cil) (×40). A: Hyperplastic smooth muscle cells, B: Increase in wall thickness. CH: Chronic hypoxia, Cil: Cilnidipine
Figure 4Photomicrograph of muscular artery stained with hematoxylin and eosin stain from (a) Group 1 (control) (×10); (b) Group 1 (control) (×40); (c) Group 2 (CH) (×10); (d) Group 2 (CH) (×40); (e) Group 3 (Cil) (×10); (f) Group 3 (Cil) (×40); (g) Group 4 (CH + Cil) (×10); (h) Group 4 (CH + Cil) (×40). A: Increased wall thickness. CH: Chronic hypoxia, Cil: Cilnidipine
Comparison of normalized wall index of coronary artery
| Parameter | Group 1 (control) | Group 2 (CH) | Group 3 (Cil) | Group 4 (CH+Cil) | ANOVA | |
|---|---|---|---|---|---|---|
| NWI | 0.620±0.02a | 0.71±0.01b | 0.55±0.02c | 0.54±0.02c | 83.935 | 0.000* |
Values are presented as mean±SD (n=6 in each group). Intergroup comparison of each parameter is presented horizontally. Horizontally the superscripts a, b, c are indicative of values that differ significantly from one another (P<0.05). *P<0.05. NWI=Normalized wall index